Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter P Jeske

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 9, 2006
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implicationsJyothi Maddineni, Jeanine M Walenga, Walter P Jeske, et al.
Seminars in Thrombosis and Hemostasis|January 5, 2005
Generic low-molecular-weight heparins: some practical considerationsJawed Fareed, Wendy L Leong, Debra A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 24, 2012
Comparative studies on branded enoxaparin and a US generic version of enoxaparinJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.
British Journal of Haematology|August 2, 2008
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopeniaJeanine M Walenga, Margaret Prechel, Walter P Jeske, et al.
Seminars in Thrombosis and Hemostasis|April 9, 2008
Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparinsWalter P Jeske, Jeanine M Walenga, Debra A Hoppensteadt, et al.
Thrombosis Research|April 18, 2002
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgGBrian Untch, Sarfraz Ahmad, Walter P Jeske, et al.
Current Pharmaceutical Design|May 17, 2007
Heparin oligosaccharides as potential therapeutic agents in senile dementiaQing Ma, Umberto Cornelli, Israel Hanin, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Antiplatelet agents: current drugs and future trendsHarry L Messmore, Walter P Jeske, William Wehrmacher, et al.
Thrombosis Research|April 5, 2011
A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparinWalter P Jeske, Debra Hoppensteadt, Angel Gray, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 26, 2007
Isolation and characterization of heparin from tuna skinsWalter P Jeske, Meredith K McDonald, Debra A Hoppensteadt, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 9, 2006
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implicationsJyothi Maddineni, Jeanine M Walenga, Walter P Jeske, et al.
Seminars in Thrombosis and Hemostasis|January 5, 2005
Generic low-molecular-weight heparins: some practical considerationsJawed Fareed, Wendy L Leong, Debra A Hoppensteadt, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 24, 2012
Comparative studies on branded enoxaparin and a US generic version of enoxaparinJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.
British Journal of Haematology|August 2, 2008
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopeniaJeanine M Walenga, Margaret Prechel, Walter P Jeske, et al.
Seminars in Thrombosis and Hemostasis|April 9, 2008
Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparinsWalter P Jeske, Jeanine M Walenga, Debra A Hoppensteadt, et al.
Thrombosis Research|April 18, 2002
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgGBrian Untch, Sarfraz Ahmad, Walter P Jeske, et al.
Current Pharmaceutical Design|May 17, 2007
Heparin oligosaccharides as potential therapeutic agents in senile dementiaQing Ma, Umberto Cornelli, Israel Hanin, et al.
Hematology/Oncology Clinics of North America|January 11, 2005
Antiplatelet agents: current drugs and future trendsHarry L Messmore, Walter P Jeske, William Wehrmacher, et al.
Thrombosis Research|April 5, 2011
A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparinWalter P Jeske, Debra Hoppensteadt, Angel Gray, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 26, 2007
Isolation and characterization of heparin from tuna skinsWalter P Jeske, Meredith K McDonald, Debra A Hoppensteadt, et al.
Pageof 5